Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.

Revenue
+1,349.1%
EPS
+13.3%
Free cash flow
−43.5%

Quarter to June 2026, against a year earlier

276.75 14.16 +5.39%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a

Praxis Precision Medicines, Inc. 10-K filed Feb 19, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 8:02 AM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Feb 28, 2025: 15 added · 15 removed · 165 modified; 1 with only figures updated